Correct Answer: C. It should not be administered in sickle cell patients
Pegylated filgrastim (pegfilgrastim) is a long-acting G-CSF analog created by covalent attachment of polyethylene glycol (PEG) to filgrastim, extending its half-life from 3–4 hours to ~15–20 hours. This allows once-per-chemotherapy-cycle dosing instead of daily injections. However, pegfilgrastim carries a critical contraindication in sickle cell disease patients. G-CSF stimulates rapid mobilization and proliferation of neutrophils, which increases blood viscosity and promotes sickling crises by enhancing vaso-occlusion. Indian guidelines and international hematology literature (including Harrison) explicitly warn against G-CSF use in sickle cell patients due to increased risk of acute chest syndrome, stroke, and multi-organ infarction. Standard filgrastim is also contraindicated, but pegfilgrastim's prolonged action and higher sustained G-CSF levels make the risk even more pronounced. In Indian clinical practice, where sickle cell disease is endemic in certain populations (tribal regions, parts of Central India), this contraindication is clinically relevant and frequently tested. The mechanism is not allergy or inefficacy, but rather the pathophysiological consequence of G-CSF-induced neutrophil mobilization in a disease characterized by hemolysis and vaso-occlusion.
Why the other options are wrong
A. Duration of action is shorter than normal filgrastim — This is the opposite of the truth. Pegylation is specifically designed to prolong duration of action—pegfilgrastim lasts 15–20 hours versus filgrastim's 3–4 hours. This is the entire pharmacological advantage of pegylation. NBE may trap students who confuse pegylation with rapid-onset formulations or who misread 'shorter' as a feature. B. It is not effective in the treatment of severe neutropenia — Pegfilgrastim is highly effective in severe neutropenia and chemotherapy-induced neutropenia (CIN). It is FDA-approved and widely used in Indian oncology centers for this indication. The trap here is confusing contraindication (sickle cell) with inefficacy. Pegfilgrastim works; it is simply unsafe in certain patient populations. D. Added advantage is that it can be taken orally — Pegfilgrastim is administered only by subcutaneous injection; it cannot be taken orally because G-CSF is a protein and is degraded by gastric enzymes. Oral G-CSF formulations do not exist in clinical practice. This is a straightforward factual distractor with no clinical basis.
High-Yield Facts
- Pegfilgrastim half-life: ~15–20 hours (vs. filgrastim 3–4 hours); allows once-per-cycle dosing in chemotherapy.
- Mechanism of contraindication in sickle cell: G-CSF mobilizes neutrophils → increased blood viscosity → vaso-occlusive crisis, acute chest syndrome, stroke.
- Pegfilgrastim is effective in chemotherapy-induced neutropenia (CIN) and severe congenital/acquired neutropenia; contraindication is patient-specific, not drug-specific.
- Route of administration: Subcutaneous injection only; protein hormone, not orally bioavailable.
- Indian clinical relevance: Sickle cell disease endemic in tribal populations and Central India; pegfilgrastim contraindication is high-yield for Indian exam context.
Mnemonics
PEG = Prolonged, Effective, G-CSF Pegfilgrastim = PEG-modified filgrastim → Prolonged half-life (15–20 hrs), Effective in CIN, but G-CSF contraindicated in sickle cell (vaso-occlusion risk). Use this to remember: pegylation extends duration, but doesn't change the drug's fundamental contraindications. SCD + G-CSF = CRISIS Sickle Cell Disease + G-CSF = vaso-occlusive CRISIS. G-CSF mobilizes neutrophils → viscosity ↑ → sickling ↑. Avoid pegfilgrastim (and filgrastim) in sickle cell patients.
NBE Trap
NBE pairs pegfilgrastim with "advantage" language (longer duration, once-per-cycle dosing) to lure students into overlooking its critical contraindication in sickle cell disease. Students may also confuse "contraindication" (unsafe in certain patients) with "inefficacy" (doesn't work), leading them to incorrectly choose option B.
Clinical Pearl
In Indian oncology centers, pegfilgrastim is standard-of-care for preventing febrile neutropenia in high-risk chemotherapy patients. However, before prescribing, always screen for hemoglobinopathies—sickle cell disease is endemic in tribal populations and parts of Central India, and a single dose of pegfilgrastim can precipitate life-threatening vaso-occlusive crisis.
_Reference: Harrison Ch. 101 (Hematopoietic Agents); KD Tripathi Ch. 47 (Immunomodulators & Hematopoietic Agents)_